Effect of lamivudine treatment on survival of 309 North American patients awaiting liver transplantation for chronic hepatitis B

Liver Transplantation

Volumn 8, Issue 5, 2002, Pages 433-439

  Fontana, Robert J ^a   Keeffe, Emmet B ^b   Carey, William ^c   Fried, Michael ^d   Reddy, Rajender ^e   Kowdley, Kris V ^f   Soldevila Pico, Consuelo ^g   McClure, Leslie A ^a   Lok, Anna S F ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

^e UNIVERSITY OF MIAMI   (United States)

^f UNIVERSITY OF WASHINGTON   (United States)

^g UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ANTIVIRUS AGENT; BILIRUBIN; FAMCICLOVIR; HEPATITIS B ANTIBODY; HEPATITIS B(E) ANTIGEN; HEPATITIS C ANTIBODY; HUMAN SERUM ALBUMIN; LAMIVUDINE; VIRUS DNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIGEN DETECTION; ARTICLE; CHRONIC HEPATITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; ETHNOLOGY; FEMALE; GENDER; GRAFT INFECTION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FAILURE; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; NORTH AMERICA; PATIENT SELECTION; PREDICTION; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; REGRESSION ANALYSIS; RISK BENEFIT ANALYSIS; SCORING SYSTEM; SURVIVAL RATE; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 0036096895     PISSN: 15276465     EISSN: None     Source Type: Journal    
DOI: 10.1053/jlts.2002.32983     Document Type: Article

References (18)

1. Hepatitis B: Evolving epidemiology and implications for control
2. Annual Report of the US Scientific Registry for Organ Sharing and the Organ Procurement and Transplantation Network - Transplant Data: 1988-1997
3. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immunoglobulin./
4. A one year trial of lamivudine for chronic hepatitis B
5. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B
6. Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis B infection
7. Beneficial effects of lamivudine in hepatitis B virus related decompensated cirrhosis
8. Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: A comparative study using a matched, untreated cohort
9. Emergence and take over of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy
10. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective
11. Outcome of lamivudine resistant hepatitis virus infection in the liver transplant recipient
12. Successful orthotopic liver transplantation for lamivudine-associated YMDD mutant hepatitis B virus
13. Liver transplantation in patients with hepatitis B virus infection: Outcome in Asians versus whites
14. A model to predict survival in patients with end-stage liver disease
15. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts
16. Determinants of survival in 133 patients with decompensated chronic hepatitis B treated with lamivudine
17. A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B
18. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants